Pleiotropic effects of lipid genes on plasma glucose, hba1c, and homa-ir levels

Diabetes

Volumn 63, Issue 9, 2014, Pages 3149-3158

  Li, Naishi ^a,b   Van Der Sijde, Marijke R ^a   Bakker, Stephan J L ^a   Dullaart, Robin P F ^c   Van Der Harst, Pim ^a   Gansevoort, Ron T ^c   Elbers, Clara C ^a,d,e   Wijmenga, Cisca ^b   Snieder, Harold ^e   Hofker, Marten H ^c   Fu, Jingyuan ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; TRIACYLGLYCEROL;

ADULT; ALLELE; APOB GENE; APOE C1 GENE; APOE C2 GENE; ARTICLE; CETP GENE; CYP7A1 GENE; DYSLIPIDEMIA; FEMALE; GCKR GENE; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HOMA IR SCORE; HUMAN; HUMAN EXPERIMENT; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; METABOLIC REGULATION; MLXIPL GENE; NORMAL HUMAN; PLEIOTROPY; PLTP GENE; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TIMD4 GENE;

BLOOD GLUCOSE; COHORT STUDIES; DYSLIPIDEMIAS; FASTING; GENETIC PREDISPOSITION TO DISEASE; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; LIPIDS; MODELS, BIOLOGICAL; POLYMORPHISM, SINGLE NUCLEOTIDE; TRIGLYCERIDES;

EID: 84906673427     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1800     Document Type: Article

References (38)

1. Risérus U, Arnlöv J, Berglund L. Long-term predictors of insulin resistance:role of lifestyle and metabolic factors in middle-Aged men. Diabetes Care 2007; 30:2928-2933
2. Wilson PWF, D'Agostino RB, Fox CS, Sullivan LM, Meigs JB. Type 2 diabetes risk in persons with dysglycemia: the Framingham Offspring Study. Diabetes Res Clin Pract 2011;92:124-127
3. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-362
4. Tenenbaum H, Behar S, Boyko V, et al. Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes. Atherosclerosis 2007;194:265-271
5. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010;466:707-713
6. Willer CJ, Schmidt EM, Sengupta S, et al.; Global Lipids Genetics Consortium. Discovery and refinement of loci associated with lipid levels. Nat Genet 2013;45:1274-1283
7. Wolfs MGM, Li N, Fu J, et al. Genetic insights through genome wide association studies in type 2 diabetes mellitus will lead to new therapeutics. In Advances in Genome Science: Changing Views on Living Organisms. Neri C, Ed. Bentham Science Publishers, 2013, p. 210-240
8. Manning AK, Hivert M-F, Scott RA, et al.; DIAbetes Genetics Replication And Meta-Analysis (DIAGRAM) Consortium; Multiple Tissue Human Expression Resource (MUTHER) Consortium. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet 2012;44:659-669
9. McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med 2010; 363:2339-2350
10. Soranzo N, Sanna S, Wheeler E, et al.; WTCCC. Common variants at 10 genomic loci influence hemoglobin A1(C) levels via glycemic and nonglycemic pathways. Diabetes 2010;59:3229-3239
11. Dupuis J, Langenberg C, Prokopenko I, et al.; DIAGRAM Consortium; GIANT Consortium; Global BPgen Consortium. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010; 42:105-116
12. Voight BF, Scott LJ, Steinthorsdottir V, et al.; MAGIC investigators; GIANT Consortium. Twelve type 2 diabetes susceptibility loci identified through largescale association analysis. Nat Genet 2010;42:579-589
13. Morris AP, Voight BF, Teslovich TM, et al.; Wellcome Trust Case Control Consortium; Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Investigators; Genetic Investigation of ANthropometric Traits (GIANT) Consortium. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 2012;44:981-990
14. Scott RA, Lagou V, Welch RP, et al.; DIAbetes Genetics Replication and Meta-Analysis (DIAGRAM) Consortium. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet 2012;44:991-1005
15. Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 2004;33:30-42
16. De Silva NMG, Freathy RM, Palmer TM, et al. Mendelian randomization studies do not support a role for raised circulating triglyceride levels influencing type 2 diabetes, glucose levels, or insulin resistance. Diabetes 2011;60:1008-1018
17. Qi Q, Liang L, Doria A, Hu FB, Qi L. Genetic predisposition to dyslipidemia and type 2 diabetes risk in two prospective cohorts. Diabetes 2012;61:745-752
18. Stolk RP, Rosmalen JGM, Postma DS, et al. Universal risk factors for multifactorial diseases: LifeLines: A three-generation population-based study. Eur J Epidemiol 2008;23:67-74
19. Jansen H, Stolk RP, Nolte IM, Kema IP, Wolffenbuttel BHR, Snieder H. Determinants of HbA1c in nondiabetic Dutch adults: genetic loci and clinical and lifestyle parameters, and their interactions in the LifeLines Cohort Study. J Intern Med 2013;273:283-293
20. Klaver EI, van Loon HCM, Stienstra R, et al. Thyroid hormone status and health-related quality of life in the LifeLines Cohort Study. Thyroid 2013;23: 1066-1073
21. Dullaart RPF, Perton F, van der Klauw MM, Hillege HL, Sluiter WJ; PREVEND Study Group. High plasma lecithin:cholesterol acyltransferase activity does not predict low incidence of cardiovascular events: possible attenuation of cardioprotection associated with high HDL cholesterol. Atherosclerosis 2010;208: 537-542
22. Oterdoom LH, de Vries APJ, Gansevoort RT, de Jong PE, Gans ROB, Bakker SJL. Fasting insulin is a stronger cardiovascular risk factor in women than in men. Atherosclerosis 2009;203:640-646
23. Browning BL, Browning SR. A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. Am J Hum Genet 2009;84:210-223
24. Filhoulaud G, Guilmeau S, Dentin R, Girard J, Postic C. Novel insights into ChREBP regulation and function. Trends Endocrinol Metab 2013;24: 257-268
25. Yamashita H, Takenoshita M, Sakurai M, et al. A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. Proc Natl Acad Sci U S A 2001;98:9116-9121
26. Herman MA, Peroni OD, Villoria J, et al. A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature 2012;484:333-338
27. Eissing L, Scherer T, Tödter K, et al. De novo lipogenesis in human fat and liver is linked to ChREBP-b and metabolic health. Nat Commun 2013;4:1528
28. Beer NL, Tribble ND, McCulloch LJ, et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 2009;18:4081-4088
29. Vaxillaire M, Cavalcanti-Proença C, Dechaume A, et al.; DESIR Study Group. The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population. Diabetes 2008;57:2253-2257
30. Benhamed F, Denechaud P-D, Lemoine M, et al. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J Clin Invest 2012;122:2176-2194
31. Dentin R, Benhamed F, Hainault I, et al. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes 2006; 55:2159-2170
32. Shindo N, Fujisawa T, Sugimoto K, et al. Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model. J Hepatol 2010;52:903-912
33. Saxena R, Elbers CC, Guo Y, et al.; Look AHEAD Research Group; DIAGRAM consortium. Large-scale gene-centric meta-Analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet 2012;90:410-425
34. Palmer CNA, Maglio C, Pirazzi C, et al. Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. PLoS One 2012;7:e39362
35. van Vliet-Ostaptchouk JV, den Hoed M, Luan J, et al. Pleiotropic effects of obesity-susceptibility loci on metabolic traits: A meta-Analysis of up to 37,874 individuals. Diabetologia 2013;56:2134-2146
36. Solovieff N, Cotsapas C, Lee PH, Purcell SM, Smoller JW. Pleiotropy in complex traits: challenges and strategies. Nat Rev Genet 2013;14:483-495
37. Carter AJR, Nguyen AQ. Antagonistic pleiotropy as a widespread mechanism for the maintenance of polymorphic disease alleles. BMC Med Genet 2011; 12:160
38. Avelar AT, Perfeito L, Gordo I, Ferreira MG. Genome architecture is a selectable trait that can be maintained by antagonistic pleiotropy. Nat Commun 2013;4:2235